Table 2. Clinical characteristics of TB/HIV co-infected children at University of Gondar Comprehensive Specialized Hospital Northwest Ethiopia, from February 2005 to March 20017 (n = 271).
| Characteristics | Total N (%) N = 271 |
Death N (%) N = 38 |
Censored N (%) N = 233 |
|
|---|---|---|---|---|
| Baseline WHO stage | I & II | 34(12.55) | 3(1.11) | 31(11.40) |
| III & IV | 237(87.45) | 35(12.90) | 202(74.54) | |
| ART Eligibility criteria | CD4+ cell | 37(13.65) | 4(1.48) | 33(12.80) |
| WHO stage | 104(38.38) | 11(4.06) | 93(34.32) | |
| Both | 125(46.13) | 23(8.49) | 102(37.32) | |
| Not recorded | 5(1.85) | 0(0) | 5(1.85) | |
| Initial ART regiment based on NRTIs | ABC-based | 10(3.69) | 5(1.85) | 5(1.85) |
| AZT-based | 185(68.27) | 20(7.38) | 165(60.89) | |
| D4T-based | 67(24.72) | 12(4.43) | 55(20.30) | |
| TDF-based | 9(3.32) | 1(0.37) | 8(2.95) | |
| Initial ART regiments based on NNRTs | EFV-based | 102(37.64) | 12(4.43) | 90(33.21) |
| NVP, PI and other based | 169(62.36) | 26(9.59) | 143(52.77) | |
| Initial regiment change | Yes | 95(35.06) | 13(4.80) | 82(30.26) |
| No | 176(64.94) | 25(9.23) | 151(55.72) | |
| Reason for regiment change | Side effect/toxicities | 23(24.21) | 6(6.32) | 17(17.89) |
| Treatment failure | 2(2.11) | 0(0) | 2(2.11) | |
| TB | 33(34.74) | 5(5.26) | 28(29.47) | |
| Stock out | 37(38.95) | 2(2.11) | 35(36.84) | |
| Treatment failure | Yes | 28(10.33) | 5(1.85) | 23(8.49) |
| No | 243(89.67) | 33(12.18) | 210(77.49) | |
| Immunologic failure | Yes | 20(7.38) | 4(1.48) | 16(5.90) |
| No | 251(92.62) | 34(12.55) | 217(80.07) | |
| Virologic failure | Yes | 17(6.27) | 3(1.11) | 14(5.17) |
| No | 254(93.73) | 35(12.92) | 219(80.81) | |
| Clinical failure | Yes | 5(1.85) | 3(1.11) | 2(0.74) |
| No | 266(98.15) | 35(12.92) | 233(85.24) | |
| Baseline HIV associated Immunosuppression status | Non-significant/Mild | 87(32.10) | 8(2.95) | 79(29.15) |
| Advanced | 73(26.95) | 8(2.95) | 65(23.99) | |
| Sever | 111(40.96) | 22(8.12) | 89(32.84) | |
| Isoniazid | Yes | 97(35.79) | 6(2.21) | 91(33.58) |
| No | 174(64.21) | 32(11.81) | 142(52.40) | |
| Hemoglobing/dl | <10 | 48(17.70) | 14(5.17) | 34(12.50) |
| > = 10 | 223(82.29) | 24(8.86) | 199(73.43) | |
| Co-trimoxazole preventive therapy | Yes | 236(87.08) | 28(10.33) | 208(76.75) |
| No | 35(12.92) | 10(3.69) | 25(9.23) | |
| Weight for age | Normal | 77(28.41) | 12(4.43) | 65(23.99) |
| Underweight | 194(71.59) | 26(9.59) | 168(61.99) | |
| Height for age | Normal | 110(40.59) | 14(5.17) | 96(35.42) |
| Stunting | 161(59.41) | 24(8.86) | 137(50.55) | |
| Adherence | Good | 231(85.24) | 23(8.49) | 208(76.75) |
| Fair | 27(9.96) | 12(4.43) | 15(5.53) | |
| Poor | 13(4.80) | 3(1.11) | 10(3.69) | |
| Site of TB | PTB | 186(68.63) | 13(4.80) | 173(63.84) |
| EPTB | 85(31.37) | 25(9.23) | 60(22.14) | |
| Time at which TB is developed | PRE ART | 206(76.01) | 25(9.23) | 181(66.79) |
| ART | 65(23.99) | 13(4.80) | 52(19.19) | |